Clinical characteristics of the first and second COVID-19 waves in the Bronx, New York: A retrospective cohort study.
Bronx
COVID-19
Coronavirus
Ethnicity
Mortality
Race
Resurgence
SARS-CoV-2
Journal
Lancet regional health. Americas
ISSN: 2667-193X
Titre abrégé: Lancet Reg Health Am
Pays: England
ID NLM: 9918232503006676
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
19
04
2021
revised:
08
07
2021
accepted:
22
07
2021
pubmed:
24
8
2021
medline:
24
8
2021
entrez:
23
8
2021
Statut:
ppublish
Résumé
There is limited clinical patient data comparing the first and second waves of the coronavirus disease 2019 (COVID-19) in the United States and the effects of a COVID-19 resurgence on different age, racial and ethnic groups. We compared the first and second COVID-19 waves in the Bronx, New York, among a racially and ethnically diverse population. Patients in this retrospective cohort study were included if they had a laboratory-confirmed SARS-CoV-2 infection by a real-time PCR test of a nasopharyngeal swab specimen detected between March 11, 2020, and January 21, 2021. Main outcome measures were critical care, in-hospital acquired disease and death. Patient demographics, comorbidities, vitals, and laboratory values were also collected. A total of 122,983 individuals were tested for SARS-CoV-2 infection, of which 12,659 tested positive. The second wave was characterized by a younger demographic, fewer comorbidities, less extreme laboratory values at presentation, and lower risk of adverse outcomes, including in-hospital mortality (adj. OR = 0·23, 99·5% CI = 0·17 to 0·30), hospitalization (adj. OR = 0·65, 99·5% CI = 0·58 to 0·74), invasive mechanical ventilation (adj. OR = 0·70, 99·5% CI = 0·56 to 0·89), acute kidney injury (adj. OR = 0·62, 99·5% CI = 0·54 to 0·71), and length of stay (adj. OR = 0·71, 99·5% CI = 0·60 to 0·85), with Black and Hispanic patients demonstrating most improvement in clinical outcomes. The second COVID-19 wave in the Bronx exhibits improved clinical outcomes compared to the first wave across all age, racial, and ethnic groups, with minority groups showing more improvement, which is encouraging news in the battle against health disparities.
Sections du résumé
BACKGROUND
BACKGROUND
There is limited clinical patient data comparing the first and second waves of the coronavirus disease 2019 (COVID-19) in the United States and the effects of a COVID-19 resurgence on different age, racial and ethnic groups. We compared the first and second COVID-19 waves in the Bronx, New York, among a racially and ethnically diverse population.
METHODS
METHODS
Patients in this retrospective cohort study were included if they had a laboratory-confirmed SARS-CoV-2 infection by a real-time PCR test of a nasopharyngeal swab specimen detected between March 11, 2020, and January 21, 2021. Main outcome measures were critical care, in-hospital acquired disease and death. Patient demographics, comorbidities, vitals, and laboratory values were also collected.
FINDINGS
RESULTS
A total of 122,983 individuals were tested for SARS-CoV-2 infection, of which 12,659 tested positive. The second wave was characterized by a younger demographic, fewer comorbidities, less extreme laboratory values at presentation, and lower risk of adverse outcomes, including in-hospital mortality (adj. OR = 0·23, 99·5% CI = 0·17 to 0·30), hospitalization (adj. OR = 0·65, 99·5% CI = 0·58 to 0·74), invasive mechanical ventilation (adj. OR = 0·70, 99·5% CI = 0·56 to 0·89), acute kidney injury (adj. OR = 0·62, 99·5% CI = 0·54 to 0·71), and length of stay (adj. OR = 0·71, 99·5% CI = 0·60 to 0·85), with Black and Hispanic patients demonstrating most improvement in clinical outcomes.
INTERPRETATION
CONCLUSIONS
The second COVID-19 wave in the Bronx exhibits improved clinical outcomes compared to the first wave across all age, racial, and ethnic groups, with minority groups showing more improvement, which is encouraging news in the battle against health disparities.
Identifiants
pubmed: 34423331
doi: 10.1016/j.lana.2021.100041
pii: S2667-193X(21)00033-8
pmc: PMC8367084
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100041Informations de copyright
© 2021 The Author(s). Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
None.
Références
Clin Chim Acta. 2020 Oct;509:91-94
pubmed: 32511972
MMWR Morb Mortal Wkly Rep. 2020 Jun 26;69(25):790-794
pubmed: 32584797
JAMA. 2020 Sep 8;324(10):998-1000
pubmed: 32789492
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Nephrol Dial Transplant. 2012 Dec;27(12):4263-72
pubmed: 23045432
Med Sci Monit. 2013 Dec 10;19:1131-41
pubmed: 24322721
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
EClinicalMedicine. 2021 Feb;32:100713
pubmed: 33495751
Infect Dis (Lond). 2021 May;53(5):370-375
pubmed: 33560897
JAMA. 2020 Jun 23;323(24):2466-2467
pubmed: 32391864
Thromb Res. 2021 Mar;199:143-148
pubmed: 33535120
J Med Virol. 2021 Feb;93(2):934-944
pubmed: 32706426
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Sci Rep. 2020 Nov 3;10(1):18909
pubmed: 33144595
Am J Emerg Med. 2021 Jan;39:173-179
pubmed: 33069541
Am J Emerg Med. 2020 Sep;38(9):1722-1726
pubmed: 32738466
J Infect. 2021 Apr;82(4):84-123
pubmed: 33152376
J Am Geriatr Soc. 2020 Oct;68(10):2153-2162
pubmed: 32735036
Emerg Infect Dis. 2006 Jan;12(1):15-22
pubmed: 16494711
Behav Med. 2019 Apr-Jun;45(2):102-117
pubmed: 31343960
JAMA. 2020 Jun 2;323(21):2192-2195
pubmed: 32347898
J Health Care Poor Underserved. 2020;31(4):1530-1535
pubmed: 33416734
Stud Health Technol Inform. 2015;216:574-8
pubmed: 26262116
PLoS One. 2021 Mar 31;16(3):e0248029
pubmed: 33788866
Crit Care. 2021 Jan 4;25(1):3
pubmed: 33397421
EClinicalMedicine. 2020 Aug;25:100455
pubmed: 32838233
J Infect Dis. 2020 May 11;221(11):1749-1751
pubmed: 32193550
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
BMC Public Health. 2011 Feb 25;11 Suppl 1:S2
pubmed: 21356131
JAMA. 2020 Nov 3;324(17):1723-1724
pubmed: 33031513
BMJ Open. 2021 Jan 17;11(1):e042140
pubmed: 33455936
J Racial Ethn Health Disparities. 2020 Dec;7(6):1039-1045
pubmed: 33025419
Lancet Infect Dis. 2002 Feb;2(2):111-4
pubmed: 11901642
JAMA Netw Open. 2020 Sep 1;3(9):e2019795
pubmed: 32975574